Cystic Fibrosis – CFTR Gene
Our Services
Pathology
Precision Medicine and Digital Pathology
Precision medicine refers to the use of data and genomics to tailor treatments to specific groups.
Among the major diseases where precision medicine has gained significant relevance are cancer, Mendelian diseases, and pharmacogenomics, particularly in oncology.
Some notable examples include:
Digital Pathology: Rapid and Accurate Diagnosis
Digital pathology is a dynamic, image-based environment that enables the acquisition, management and interpretation of pathology information generated from a digitized glass slide. Healthcare applications include primary diagnosis, diagnostic consultation, intraoperative diagnosis, medical student and resident training, manual and semi-quantitative review of immunohistochemistry (IHC), clinical research, diagnostic decision support, peer review, and tumor boards.
New information systems and digital scanners in laboratories digitize hundreds of samples daily, making it possible to work with generated images, known as Whole Slide Images (WSI).
A diagnostic digital pathology infrastructure can facilitate significant improvements, resulting in increased processing capacity and shorter case turnaround times, as the journey of a glass slide ends in the laboratory after digitization.
A specialized digital pathology infrastructure like that of CorePlus can potentially save laboratory technician time by eliminating the need to assemble and distribute trays of glass slides.
References:
Digital Pathology Association
Beyond Digital Pathology
Currently, CorePlus, a leader in precision pathology in Puerto Rico, has announced a partnership with Alpenglow Biosciences for the development and implementation of 3D technology enabled with Artificial Intelligence (AI).
Through this collaboration, CorePlus will employ 3D images of prostate biopsies to train AI models to recognize key tissue structures such as cancer cells, immune cells, and blood vessels.
CorePlus was the first laboratory in the Americas to implement AI in prostate cancer. This work will be overseen and led by Dr. Juan Carlos Santa Rosario, Chief Medical Officer of CorePlus.